Library / regulatory-reference
Bulgaria: Bulgarian Drug Agency (BDA)
Audience: administrators-policy, researchers-scientists ยท Review state: published
The national authority
The Bulgarian Drug Agency, known as the BDA, is Bulgaria's national regulatory authority for medicines, operating as an executive agency under the Ministry of Health.
Bulgaria's market sits inside the European single market, and the agency works within the European regulatory network while overseeing a market with a domestic pharmaceutical tradition.
How products enter the market
Medicines require marketing authorization through national or European procedures after evaluation of quality, safety and efficacy, and establishments are licensed and inspected by the agency.
Post-market work includes safety monitoring within the European alert network, with pricing and reimbursement rules playing a strong role in which products reach patients.
Regional and international role
The agency is an active member of the European regulatory network, contributing to shared scientific and inspection work.
Its experience with pricing-driven supply pressure and parallel exports mirrors that of other lower-price European markets.
Using this profile
The agency publishes regulations, registers and alerts in Bulgarian, with English material, through its official portal, which is the primary source for current rules and listed in this profile's internal reference record.
For cross-country comparison: Bulgaria illustrates the lower-price member state: European-network regulation alongside persistent price-driven availability questions.
Limitations
Educational profile of a national regulatory system, current as of drafting. It simplifies routes and classes and is not legal, regulatory, or clinical advice. Filing and compliance decisions must be confirmed against the authority's current published rules and, where needed, professional regulatory counsel.